Everolimus demonstrated disease control, tumor shrinkage in previously treated advanced gastric cancer

HemOnc today
Posted April 16, 2010

Everolimus monotherapy in previously treated patients with advanced gastric cancer was well-tolerated and demonstrated promising disease control, according to the findings of a phase-2 trial.

Researchers analyzed data from 53 patients assigned 10 mg per day everolimus (Afinitor, Novartis) taken orally until tumor progression,...

admin

Mon Feb 8, 2010 7:01pm EST

* Watchdog recommends against Afinitor, Tasigna and Sprycel

* Limited data to back benefits of three pricey drugs - NICE

LONDON, Feb 9 (Reuters) - Britain's cost-effectiveness watchdog recommended against two expensive cancer drugs from Novartis AG (NOVN.VX) and one from Bristol-Myers Squibb Co (BMY.N) being used within the state-run health service.

The National Institute for Health and Clinical Excellence (NICE) said...

admin

DUBAI, March 30 (Reuters) - U.S. regulators have approved Novartis AG's Afinitor drug for use in kidney cancer and the Swiss group expects to be effective against other disease types that could make it a billion dollar seller.

The U.S. Food and Drug Administration had requested more data on the once a day pill in November, effectively delaying its approval by three months, but now has given it the green light, Novartis said on Monday.

"Afinitor is a drug that really...

admin